Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 7/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | CBFB | Q13951 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970875 | 0.90 | NPBWR1 (0.50) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19970794 | 0.86 | NPBWR1 (0.67) | NPBWR1DGAT1KCNH2CBFBCHEK2 | |
| SCHEMBL19970744 | 0.82 | CYP1A2 (0.60) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2617470 | 0.81 | CBFB (0.66) | NPBWR1CYP3A4DGAT1KCNH2CBFB | |
| SCHEMBL3198884 | 0.81 | MEN1 (0.74) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30011996 | 0.80 | SLC2A1 (0.51) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21705326 | 0.80 | NPBWR1 (0.67) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30011485 | 0.80 | NPBWR1 (0.67) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19986735 | 0.78 | CYP1A2 (0.59) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24074350 | 0.78 | NPBWR1 (0.59) | NPBWR1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3512838-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | Centre National De La Recherche Scientifique (FR) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | NPBWR1 4485/4885CYP1A2 2067/4885CYP3A4 460/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | NPBWR1 4485/4885CYP1A2 2067/4885CYP3A4 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.